Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review

Colledge-Frisby, Samantha; Ottaviano, Sophie; Webb, Paige; Grebely, Jason; Wheeler, Alice; Cunningham, Evan B; Hajarizadeh, Behzad; Leung, Janni; Peacock, Amy; Vickerman, Peter; Farrell, Michael; Dore, Greg; Hickman, Matthew; Degenhardt, Louisa

doi:10.1016/s2214-109x(23)00058-x

Cited by 50 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As per the recent systematic review, 93 countries are implementing NSEP, while 90 countries are implementing OAT in 2022. [ 5 ] A total of 17 countries have supervised DCR, 43 countries have naloxone distribution services, and 26 have drug-checking services. Globally, 18 out of 100 people who inject drugs (PWID) receive OAT, while 35 needles and syringes are distributed per PWID per year.…”

Section: Global Status Of Harm Reductionmentioning

confidence: 99%

“…Among PWID who inject primarily opioids, the coverage is 4 per 100 PWID. [ 5 ] Thus, the coverage of OAT is extremely low in India and falls under the low coverage category of the WHO ((low <20 people; moderate 20–39 people; high ≥40 people).…”

Section: Indian Status Of Harm Reductionmentioning

confidence: 99%

“…[ 14 ] On the other hand, there were 277 NSEP sites. [ 5 ] Around 39,235,718 new needles and 27,917,942 new syringes were distributed among PWID during the 2021–2022 period. One-time coverage of about 80% has been reached during NACP-III.…”

Section: Indian Status Of Harm Reductionmentioning

confidence: 99%

See 2 more Smart Citations

Current status of harm reduction in India: Are we doing enough?

Parmar,

Chakraborty,

Balhara

2024

Indian Journal of Psychiatry

View full text Add to dashboard Cite

Section: Global Status Of Harm Reductionmentioning

confidence: 99%

Section: Indian Status Of Harm Reductionmentioning

confidence: 99%

See 1 more Smart Citation

Current status of harm reduction in India: Are we doing enough?

Parmar,

Chakraborty,

Balhara

2024

Indian Journal of Psychiatry

View full text Add to dashboard Cite

“…This is despite the availability of a range of evidence-based harm reduction interventions including sterile needle and syringe programs (NSP) and opioid agonist therapy (OAT), both of which have been shown to reduce the risk of hepatitis C (van Santen et al , 2023). OAT and NSP however remain underfunded and, in many cases, opposed outright in a range of settings globally with only five countries worldwide defined as providing adequate coverage of both (Colledge-Frisby et al , 2023).…”

Section: Introductionmentioning

confidence: 99%

“No, my name’s not on the lease at all”: an interpretive phenomenological analysis of unstable housing and hepatitis C among people who inject drugs

McColl,

Higgs,

Harney

2024

DHS

View full text Add to dashboard Cite

Purpose Globally, hepatitis C treatment uptake is lower among people who are homeless or unstably housed compared to those who are housed. Understanding and addressing this is essential to ensure no one is left behind in hepatitis C elimination efforts. This study aims to explore peoples’ experiences of unstable housing and health care, and how these experiences influenced engagement in hepatitis C treatment. Design/methodology/approach Purposive sampling was used to recruit people with lived experience of injection drug use, hepatitis C and unstable housing in Melbourne, Australia. In-depth semistructured interviews were conducted and a case study approach with interpretative phenomenological analysis was used to identify personal experiential themes and group experiential themes. Findings Four people were interviewed. The precarious nature of housing for women who inject drugs was a group experiential theme, however, this did not appear to be a direct barrier to hepatitis C treatment. Rather, competing priorities, including caregiving, were personal experiential themes and these created barriers to treatment. Another group experiential theme was “right place, right time, right people” with these three elements required to facilitate hepatitis C treatment. Originality/value There is limited research providing in-depth insight into how personal experiences with unstable housing and health care shape engagement with hepatitis C treatment. The analyses indicate there is a need to move beyond a “one size fits-all” approach to hepatitis C care. Instead, care should be tailored to the needs of individuals and their personal circumstances and regularly facilitated. This includes giving greater attention to gender in intervention design and evaluation, and research more broadly.

show abstract

“…Access to HIV and viral hepatitis services for people who inject drugs has stagnated, despite their vulnerability to HIV and viral hepatitis being well recognised. This vulnerability has provoked repeated calls for increased access to HIV and viral hepatitis prevention services, including harm reduction interventions, most of which seem to have gone unheeded according to new research published in The Lancet March 2023 by Degenhardt et al [1] and College-Frisby et al [2].…”

mentioning

confidence: 99%